Magaldrate (malumix) is a chemical combination of magnesium and aluminum hydroxides used an antacid. It has a rapid action, high acid consuming capacity. Studies in vitro showed that magaldrate (malumix) possessed some antipepsin activity. At pH = 1.5 proteolysis was inhibited 55% by malumix. Pretreatment with Malumix suspension 30 minutes before ethanol reduced the severity and extent of gastric mucosal lesions at dose-dependent manner. Magaldrate (malumix) had not acute toxicity in vivo test.
Peptic Ulcer ; Therapeutics ; Magaldrate ; Pharmaceutical Preparations

Magaldrat, a chemical combination of aluminum and magnesium hydroxides was synthesized from aluminum compounds and magnesium sulfate. The factors, which influence the result, have been investigated. The quality of magaldrate has also been analyzed following the standards of USP XXIII. The product showed low acute and chronic toxicity in vivo.
Stomach Diseases ; Aluminum ; therapeutics ; Pharmaceutical Preparations

The acute toxicity of Bimix (CBS) has been tested on mice at the dose of 1.25g/kg once time daily. This dose was equivalent to dose of 73 times the daily therapeutic dose on body weight. No toxic effects were seen. Acute toxicity appeared to be virtually nil. The semi-acute has also tested on mice at the dose 0.125g/kg once daily for 45 days. No accumulated toxicity was observed. No lesion or damage were apparent in the liver and kidneys. The results of experiment showed that CBS could be used for a long time with a little change on haematology and biochemical indices
Pharmaceutical Preparations ; toxicity

Bimix - a produce of CBS have been prepared and tested for inhibitory activity against E. coli, P. aeruginosa, Staphylococcus aureus and Streptococcus faecalis. The efficacy of Bimix also was compared with Gastrostat and Trymo. They had only bactericidal activity in Streptococcus - faecalis. The range of the minimum inhibitory concentration (MIC) for CBS (Bimix) against some H. pylori was 2-32 g/ml
Helicobacter pylori ; therapy ; Anti-Bacterial Agents ; tablets

Malumix, an antiacid uncoated tablet, contains Magaldrate as the biological active agent. Its optimal formula was established by using the artificial intelligent software CAD/CHEM 4.6, based on the experimental data of nine designed formulae. The experimental properties of the above dosage form were almost the same in comparison with its predicted ones.
Chemistry, Pharmaceutical ; Artificial Intelligence

The first Viet Nam baby born from intracytoplasmic sperm injection using testicular sperm from impaired spermatogenesis testes in 1/3/2004. There was approximately 50000 sperm after preparation, among them 20% was motile. From 12 retrieved oocytes, 11 were mature and therefore injected. Five oocytes fertilized and developed into 4 embryos. Embryo transfer was carried out for all 4 embryos. One embryo implanted and kept growing till the 37th week of pregnancy. Patient underwent ceasarian section
Spermatogenesis ; Sperm Retrieval ; Sperm Injections, Intracytoplasmic

A new compound, 3β-acetoxylanosta-7,9(11),24-triene-26-al (3), and seven known compounds (1 – 2 and 4 – 8) were isolated from Ganoderma tropicum (Jung.) Bres. collected in Tay Nguyen, Vietnam. The structures of these compounds were determined by one- and two-dimensional nuclear magnetic resonance spectroscopy, electrospray ionization mass spectrometry (ESI-MS), and high-resolution ESI-MS, and by comparison with literature data. All of the isolated compounds were tested for nitroblue tetrazolium (NBT) reduction activity in Saccharomyces cerevisiae-stimulated RAW 246.7 cells. Among them, compounds 2 – 4 and 6 – 8 enhanced the NBT reduction in a dose-dependent manner.

A new compound, 3β-acetoxylanosta-7,9(11),24-triene-26-al (3), and seven known compounds (1 – 2 and 4 – 8) were isolated from Ganoderma tropicum (Jung.) Bres. collected in Tay Nguyen, Vietnam. The structures of these compounds were determined by one- and two-dimensional nuclear magnetic resonance spectroscopy, electrospray ionization mass spectrometry (ESI-MS), and high-resolution ESI-MS, and by comparison with literature data. All of the isolated compounds were tested for nitroblue tetrazolium (NBT) reduction activity in Saccharomyces cerevisiae-stimulated RAW 246.7 cells. Among them, compounds 2 – 4 and 6 – 8 enhanced the NBT reduction in a dose-dependent manner.

Objective: To document the evolution and optimization of the Zika virus (ZIKV) disease surveillance system in southern Viet Nam in 2016 and to describe the characteristics of the identified ZIKV-positive cases. Methods: We established a sentinel surveillance system to monitor ZIKV transmission in eight sites in eight provinces and expanded the system to 71 sites in 20 provinces in southern Viet Nam in 2016. Blood and urine samples from patients who met the case definition at the sentinel sites were tested for ZIKV using real-time reverse transcription polymerase chain reaction at the Pasteur Institute in Ho Chi Minh City (PI-HCMC). We conducted descriptive analysis and mapped the ZIKV-positive cases. Results: In 2016, 2190 specimens from 20 provinces in southern Viet Nam were tested for ZIKV at PI-HCMC; 626 (28.6%), 484 (22.1%), 35 (1.6%) and 1045 (47.7%) tests were conducted in the first, second, third and fourth quarters of the year, respectively. Of these tested specimens, 214 (9.8%) were ZIKV positive with 212 (99.1%) identified in the fourth quarter. In the fourth quarter, the highest positivity rate was those in age groups 30–39 years (30.0%) and 40–59 years (31.6%). Of the 214 ZIKV-positive patients, 210 (98.1%) presented with rash, 194 (90.7%) with fever, 149 (69.6%) with muscle pain, 123 (57.5%) with joint pain and 66 (30.8%) with conjunctivitis. Discussion The surveillance system for ZIKV disease underwent several phases of optimization in 2016, guided by the most up-to-date local data. Here we demonstrate an adaptable surveillance system that detected ZIKV-positive cases in southern Viet Nam.

BACKGROUND: Resting heart rate (RHR) is considered as a strong predictor of total mortality and hospitalization due to heart failure in hypertension patients. Bisoprolol fumarate, a second-generation beta-adrenoreceptor blockers (β-blocker) is commonly prescribed drug to manage hypertension. The present study was to retrospectively evaluate changes in the average RHR and its association with cardiovascular outcomes in bisoprolol-treated coronary artery disease (CAD) patients from the CAD treated with bisoprolol (BISO-CAD) study who had comorbid hypertension. METHODS: We performed ad-hoc analysis for hypertension sub-group of the BISO-CAD study (n = 866), which was a phase IV, multination, multi-center, single-arm, observational study carried out from October 2011 to July 2015 across China, South Korea, and Vietnam. Multivariate regression analysis was used to identify factors associated with incidence of composite cardiac clinical outcome (CCCO), the results were presented as adjusted odds ratio (OR) along with 95% confidence interval (CI) and adjusted P value. RESULTS: A total of 681 patients (mean age: 64.77 ± 10.33 years) with hypertension from BISO-CAD study were included in the analysis. Bisoprolol improved CCCOs in CAD patients with comorbid hypertension, with RHR <65 and <70 beats/min compared with RHR ≥65 and ≥75 beats/min, respectively, in the efficacy analysis (EA) set. In addition, it lowered RHR in both intent-to-treat (ITT) and EA groups after 6, 12, and 18 months of treatment. Further, RHR 70 to 74 beats/min resulted in significantly higher risk of CCCOs EA set of patients (adjusted OR: 4.34; 95% CI: 1.19-15.89; P = 0.03). Also, events of hospitalization due to acute coronary syndrome were higher when RHR 69 to 74 beats/min compared to RHR <69 beats/min in ITT patients. CONCLUSION Bisoprolol can effectively reduce RHR in Asian CAD patients with comorbid hypertension and hence, improve CCCO without affecting their blood pressure.